Introduction
The diagnosis of neurological disorders has historically relied on clinical interviews, behavioral observations, and expensive, often invasive imaging techniques like MRI or CT scans. While these methods are effective, they are frequently subjective and slow. Emerging research suggests that eye-tracking technology offers a non-invasive, objective alternative for preliminary screening. By treating the eyes as a "mirror of the mind," clinicians can identify subtle oculomotor patterns that signal underlying neural dysfunction.
Methodology: A Systematization of Knowledge
This study represents a comprehensive Systematization of Knowledge (SoK), synthesizing findings from a massive meta-review of existing literature. The authors initially identified 1,692 relevant papers, ultimately narrowing the scope to 464 peer-reviewed studies that specifically investigate gaze behavior in diagnostic contexts.
The analysis spans six major neural classes, including neurodevelopmental and neurodegenerative disorders. The primary goal was to move beyond fragmented research and establish a unified set of guidelines for the eye-tracking pipeline, covering everything from participant screening to hardware requirements like sampling rates and drift correction.
Physiological Foundations
The efficacy of gaze-based diagnosis is rooted in a fundamental biological fact: approximately 50% of the brain’s neural pathways are dedicated to vision and the control of eye movements. This high level of integration makes the oculomotor system a sensitive indicator of neural health. The paper distinguishes between gaze abnormalities that are "epiphenomena" (byproducts of other deficits, such as in Dyslexia) and those that are "direct reflections" of functional network states (as seen in ADHD or ASD).
Diagnostic Mapping and Biomarkers
The core contribution of this research is the identification of specific gaze "biomarkers" associated with various disorders. By adopting a transdiagnostic framework, the authors highlight how overlapping disruptions in neural circuits—such as those governing impulsivity—manifest as distinct saccadic patterns across different conditions.
Key findings include:
- ASD: Characterized by reduced fixation on social cues (eyes/faces) and erratic saccade amplitudes.
- ADHD: Shows shorter fixation durations and "reduced inhibition," leading to more frequent, impulsive saccades.
- Alzheimer’s (AD): Marked by increased fixation duration (difficulty processing information) and unique "oblique" microsaccade behavior.
- Parkinson’s (PD): Notable for "hypometric" saccades (undershooting the target) and saccadic intrusions during smooth pursuit.
- Anxiety: Demonstrates "hypervigilance" (faster initial fixations on threats) followed by "gaze avoidance."
Challenges in Standardization
Despite the promise of eye-tracking, the field faces significant bottlenecks. Many contradictory findings in previous literature stem from methodological inconsistencies rather than biological differences. For instance, capturing micro-movements accurately requires high-frequency trackers (at least 250Hz), yet many studies utilize lower-frequency hardware (e.g., 30Hz). Standardizing these protocols is essential for moving gaze-based tools from the lab to the clinic.
Conclusion and Future Directions
Gaze tracking currently serves as a powerful preliminary indicator rather than a standalone diagnostic tool. Its future lies in multimodal integration—combining eye-tracking data with EEG, MRI, and clinical history. Furthermore, the development of AI-driven diagnostic tools, trained on standardized datasets, will be crucial for disentangling comorbid conditions and providing more accurate, real-time assessments of neural health.
Summary updated